James Lillie
Fortune : 3 M $ au 31/08/2026
Fortune : 3 M $ au 31/08/2026
James Lillie is Chief Scientific Officer at MapLight Therapeutics, Inc. since 2019.
Formerly, Dr. Lillie was Senior Director-Biology at Scriptgen Pharmaceuticals, Inc. and Chief Scientific Officer at OvaScience, Inc. in 2018.
Dr. Lillie earned a doctorate from Harvard University and completed undergraduate studies at Wesleyan University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 17/08/2026 | 210 110 ( 0,4 % ) | 3 M $ | 31/08/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| MAPLIGHT THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/02/2019 |
| Sociétés | Poste | Fin |
|---|---|---|
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of new fertility treatment options for women | Directeur Technique/Scientifique/R&D | 07/12/2018 |
Scriptgen Pharmaceuticals, Inc.
Scriptgen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops small molecule drugs | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
Scriptgen Pharmaceuticals, Inc.
Scriptgen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops small molecule drugs | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wesleyan University
Wesleyan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of new fertility treatment options for women | Health Technology |
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for debilitating central nervous system disorders | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national